Orandi At 5 years of follow-up, significantly fewer GLP-1 drug users (7.5%) than nonusers (12.2%) experienced death-censored graft loss, for a 49% lower risk for graft loss with GLP-1 drug use when adjusted for insulin use (adjusted subhazard ratio [aSHR] = 0.51
doi:10.1055/s-0029-1240884 Maki KC, Reeves MS, Farmer M, Yasunaga K, Matsuo N, Katsuragi Y, Komikado M, Tokimitsu I, Wilder D, Jones F, Blumberg JB, Cartwright Y
They sit alongside approved products in the same table but are explicitly flagged as not yet available
Which GLP-1 is right for you
Helps Expedite Fat Loss
A recent survey from the North American Neuro-Ophthalmology Society (NANOS) recently demonstrated that the median wait time to receive care for new patients, many of whom present with acute concern, is 6 weeks [1]